Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer

"The results of SERENA-2 support further development of camizestrant in ER-positive breast cancer."MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news